Evolocumab in Paediatric Heterozygous Familial Hypercholesterolaemia: Cognitive Function During 80 Weeks of Open-Label Extension Treatment
Source : https://pubmed.ncbi.nlm.nih.gov/37855448/
In paediatric patients with FH, 80 weeks of open-label evolocumab treatment had no negative impact on cognitive function.
Because cholesterol is important for development and adequate function of the brain, there is a concern that lowering cholesterol in children may affect mental ability. In this study, researchers tested whether treating children with evolocumab for 80 weeks affected mental ability in performing several tasks.
Share
PCSK9 Inhibition Ameliorates Experimental Autoimmune Myocarditis by Reducing TH17 Cell Differentiation Through LDLR/STAT-3/ROR-γT Pathway
Source : https://www.sciencedirect.com/science/article/abs/pii/S1567576923012870?via=ihub
Proprotein convertase subtilisin kexin type 9 (PCSK9) was characterized as a protein regulating circulating cholesterol metabolism; however, recent st...
PCSK9 inhibition ameliorated the severity of EAM mice by reducing Th17 cell differentiation. PCSK9 is a promising target for treating myocarditis.
Share
Real-World Insights Into Evolocumab Use in Patients With Hyperlipidemia Across Five Countries: Analysis From the ZERBINI Study
Source : https://link.springer.com/article/10.1007/s40119-023-00334-5
Introduction This study characterizes patients receiving evolocumab in clinical practice and assesses treatment effectiveness, safety and persistence outcomes across five countries. Methods This retrospective and prospective observational study enrolled patients...
These findings provide real-world evidence that evolocumab use is in accordance with its international guideline-recommended place in dyslipidemia therapy, as well as confirmation of its effectiveness and safety in a heterogeneous population. Evolocumab can address a healthcare gap in the management of dyslipidemia by increasing the...
Share
PCSK9 Inhibitors Suppress Oxidative Stress and Inflammation in Atherosclerotic Development by Promoting Macrophage Autophagy
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492065/
Objectives: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a novel class of cholesterol-lowering drugs, can reduce atherosclerosis independent of systemic lipid changes. However, the mechanism by which PCSK9 inhibition protects...
This study reveals a novel protective mechanism by which PCSK9 inhibition enhances autophagy and thereby reduces oxidative stress and inflammation in atherosclerosis.
Share
Long-Term Safety and Effectiveness of Alirocumab and Evolocumab in Familial Hypercholesterolemia (FH) in Belgium
Source : https://pubmed.ncbi.nlm.nih.gov/37767917/
Background: In 2019, the European Atherosclerosis Society (EAS) published updated guidelines, recommending even lower blood cholesterol targets than previously. In patients with familial hypercholesterolaemia (FH), who have very elevated blood...
Anti-PCSK9 mAb are a safe and effective therapeutic option for lowering LDL-C levels in FH patients. It allowed a significant portion of our FH patients to reach their lipid targets, mainly in those with combined therapy with statin and/or ezetimibe.
Share